Trials / Recruiting
RecruitingNCT06503224
An Exploratory Clinical Study of SCAR02 Targeting BCMA and CD19 for the Treatment of Refractory Autoimmune Diseases
An Exploratory Clinical Study of a Fourth-generation Autologous CAR-T Cell Injection (SCAR02) Targeting BCMA and CD19 for the Treatment of Refractory Autoimmune Diseases
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 18 (estimated)
- Sponsor
- The First Affiliated Hospital of University of Science and Technology of China · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open label, single-site, dose-escalation study in up to 18 participants with refractory autoimmune diseases. This study aims to evaluate the safety and efficacy of the treatment with Anti-BCMA and CD19 CART
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Anti-BCMA and CD19 CART cells will be injected intravenously on a one-time basis. | A single intravenous infusion of anti-BCMA and CD19 CART cells (dose-escalating infusion of 0.5-3 x10\^6 CART cells/kg）. |
Timeline
- Start date
- 2024-04-09
- Primary completion
- 2026-04-30
- Completion
- 2028-04-30
- First posted
- 2024-07-16
- Last updated
- 2025-04-24
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06503224. Inclusion in this directory is not an endorsement.